You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

Article metrics

Article menu

Download PDFPDF

XML
Oncolytic and local immunotherapy
Original research
The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

 

Online download statistics by month:

Online download statistics by month: April 2020 to June 2025

AbstractFullPdf
Apr 202017017162
May 2020550550233
Jun 202022822959
Jul 202015815848
Aug 202015415153
Sep 202019519559
Oct 202015015059
Nov 202011111151
Dec 202016116162
Jan 202112612643
Feb 202115815851
Mar 202114514552
Apr 202116916956
May 2021858548
Jun 2021848448
Jul 2021686835
Aug 2021848448
Sep 202110610658
Oct 2021787851
Nov 2021878939
Dec 2021525238
Jan 2022798335
Feb 2022707238
Mar 2022758051
Apr 2022657334
May 2022848856
Jun 2022687137
Jul 20228810042
Aug 2022687245
Sep 2022636524
Oct 2022646635
Nov 2022737836
Dec 202211211425
Jan 2023585842
Feb 2023686828
Mar 2023616227
Apr 2023333326
May 2023363723
Jun 2023434320
Jul 2023525221
Aug 2023393913
Sep 202330317
Oct 202310010015
Nov 202325825817
Dec 2023535330
Jan 2024394013
Feb 2024373721
Mar 2024494956
Apr 2024464739
May 2024353516
Jun 2024353625
Jul 2024707112
Aug 20242929159
Sep 2024192319
Oct 20243640145
Nov 2024545627
Dec 2024434316
Jan 2025434332
Feb 2025424221
Mar 2025555532
Apr 2025797916
May 2025464626
Jun 202526268
Total564257132663